Dual PPARγ/SUR agonists, such as compound 5 (Ibrahim et al., 2017a), can improve insulin sensitivity and stimulate insulin secretion simultaneously, making them an attractive therapeutic option for patients with T2DM who have insulin resistance and decreased insulin secretion. The gene discussed is INS; the disease is Insulin resistance.